BCB-276

BCB-276 is an autologous chimeric antigen receptor (CAR) T-cell therapy that targets B7-H3, a protein highly expressed in pediatric central nervous system tumors, including diffuse intrinsic pontine glioma (DIPG). It is being developed specifically for the treatment of DIPG, a fatal pediatric brainstem tumor with no approved therapies and extremely poor prognosis. The therapy involves repetitive intracerebroventricular dosing and has demonstrated promising safety and efficacy in early clinical trials. In phase 1 studies, BCB-276 showed a median overall survival of 10.7 months from infusion and 19.8 months from diagnosis among treated patients, with some long-term survivors reported. The most common adverse events were mild to moderate headaches, nausea/vomiting, fatigue, and fever; one dose-limiting toxicity (grade 4 intratumoral hemorrhage) was observed. The product has received both FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy (RMAT) designation based on these results[2][3][4][5][6][7]. BrainChild Bio plans to advance BCB-276 into a pivotal phase 2 trial as part of its registration strategy.

Brand names

BCB-276BCB276BCB 276

Other names

B7H3 CAR TB-7H3 CAR TB 7H3 CAR TB7-H3 chimeric antigen receptor T cellB-7-H3 chimeric antigen receptor T cellB 7-H3 chimeric antigen receptor T cellanti-B7-H3 CAR-Tanti-B-7-H3 CAR-Tanti-B 7-H3 CAR-TiC9-CAR.B7-H3iC-9-CAR.B7-H3iC 9-CAR.B7-H3